Patents by Inventor Dinh Diep
Dinh Diep has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200087731Abstract: Some embodiments relate to a method for detecting the presence of one or more nucleic acids indicative of a health condition, tissue of origin, germ layer of origin or organ of origin in a mixture of nucleic acids comprising performing methylation analysis on a sample comprising a plurality of nucleic acids and determining whether the sample includes a plurality of methylation haplotype blocks indicative of the presence one or more nucleic acids indicative of a health condition, tissue of origin, germ layer of origin or organ of origin wherein the methylation haplotype blocks comprise a plurality of methylation sites for which the methylation status is coordinated.Type: ApplicationFiled: December 21, 2017Publication date: March 19, 2020Inventors: Kun Zhang, Dinh Diep
-
Publication number: 20020155535Abstract: The present invention provides a polynucleotide (ncp) which identifies and encodes a novel cysteine protease (NCP) expressed in cells of both the adrenal gland and human umbilical vein endothelium. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and host cells for the production of purified NCP peptide, antibodies capable of binding to NCP, inhibitors which bind to NCP and pharmaceutical compositions based on NCP specific antibodies or inhibitors. The invention specifically provides for diagnostic assays based on altered ncp expression and which allow identification of such a condition. These assays utilize probes designed from ncp encoding or controlling nucleic acid sequences or antibodies specific for the NCP.Type: ApplicationFiled: September 28, 2001Publication date: October 24, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Dinh Diep, Scott Michael Braxton, Angelo M. Delegeane
-
Patent number: 6197519Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel pancreas-derived serpin (PDS) expressed in human pancreas. The present invention also provides for antisense molecules to the nucleotide sequences which encode PDS, expression vectors for the production of purified PDS, antibodies capable of binding specifically to PDS, hybridization probes or oligonucleotides for the detection of PDS-encoding nucleotide sequences, genetically engineered host cells for the expression of PDS, diagnostic tests based on PDS-encoding nucleic acid molecules and a pharmaceutical composition containing PDS capable of binding specifically to a serine protease.Type: GrantFiled: July 27, 1999Date of Patent: March 6, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott Michael Braxton, Craig G. Wilde, Dinh Diep
-
Patent number: 6033848Abstract: The present invention provides a polynucleotide (icel) which identifies and encodes a human ice homolog (ICEL) expressed in lung cells and tissues. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and host cells for the production of purified ICEL peptide, antibodies capable of binding to ICEL, inhibitors which bind to ICEL and pharmaceutical compositions based on ICEL specific antibodies or inhibitors. The invention specifically provides for diagnostic assays which identify a disorder or disease with altered icel expression which allows identification and monitoring of hospital patients. These assays utilize icel encoding or controlling nucleic acid sequences, fragments or oligomers thereof, or antibodies specific for the peptide.Type: GrantFiled: August 1, 1995Date of Patent: March 7, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott Michael Braxton, Dinh Diep, Jeffrey J. Seilhamer
-
Patent number: 6030791Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a human homolog of rat elastase IV (HEIV) expressed in pancreas tissue. The present invention also provides for antisense molecules to the nucleotide sequences which encode HEIV, hybridization probes or oligonucleotides for the detection of HEIV-encoding nucleotide sequences, and a diagnostic test based on HEIV-encoding nucleic acid molecules. The present invention further provides for genetically engineered host cells for the expression of HEIV, biologically active HEIV, antibodies capable for binding specifically to HEIV, and treatment methods comprising administration of compounds, such antibodies or inhibitors, capable of binding HEIV to alter its activity.Type: GrantFiled: September 15, 1998Date of Patent: February 29, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott M. Braxton, Dinh Diep, Angelo M. Delegeane
-
Patent number: 6013448Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel pancreas-derived serpin (PDS) expressed in human pancreas. The present invention also provides for antisense molecules to the nucleotide sequences which encode PDS, expression vectors for the production of purified PDS, antibodies capable of binding specifically to PDS, hybridization probes or oligonucleotides for the detection of PDS-encoding nucleotide sequences, genetically engineered host cells for the expression of PDS, diagnostic tests based on PDS-encoding nucleic acid molecules and a pharmaceutical composition containing PDS capable of binding specifically to a serine protease.Type: GrantFiled: November 25, 1997Date of Patent: January 11, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott Michael Braxton, Craig G. Wilde, Dinh Diep
-
Patent number: 6007997Abstract: The present invention provides a polynucleotide (ncp) which identifies and encodes a novel cysteine protease (NCP) expressed in cells of both the adrenal gland and human umbilical vein endothelium. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and host cells for the production of purified NCP peptide, antibodies capable of binding to NCP, inhibitors which bind to NCP and pharmaceutical compositions based on NCP specific antibodies or inhibitors. The invention specifically provides for diagnostic assays based on altered ncp expression and which allow identification of such a condition. These assays utilize probes designed from ncp encoding or controlling nucleic acid sequences or antibodies specific for the NCP.Type: GrantFiled: November 17, 1998Date of Patent: December 28, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Dinh Diep, Scott Michael Braxton, Angelo M. Delegeane
-
Patent number: 5955284Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel serpin (CAPE) expressed in human hypothalamus. The present invention also provides for antisense molecules to the nucleotide sequences which encode CAPE, expression vectors for the production of purified CAPE, antibodies capable for binding specifically to CAPE, hybridization probes or oligonucleotides for the detection of CAPE-encoding nucleotide sequences, genetically engineered host cells for the expression of Cape, a pharmaceutical composition containing biologically active CAPE, a diagnostic test based on CAPE-encoding nucleic acid molecules, and treatment methods comprising administration of biologically active CAPE.Type: GrantFiled: December 1, 1998Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott Michael Braxton, Dinh Diep, Susan G. Stuart
-
Patent number: 5929210Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel serpin (CAPE) expressed in human hypothalamus. The present invention also provides for antisense molecules to the nucleotide sequences which encode CAPE, expression vectors for the production of purified CAPE, antibodies capable for binding specifically to CAPE, hybridization probes or oligonucleotides for the detection of CAPE-encoding nucleotide sequences, genetically engineered host cells for the expression of Cape, a pharmaceutical composition containing biologically active CAPE, a diagnostic test based on CAPE-encoding nucleic acid molecules, and treatment methods comprising administration of biologically active CAPE.Type: GrantFiled: December 23, 1997Date of Patent: July 27, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott Michael Braxton, Dinh Diep, Susan G. Stuart
-
Patent number: 5856109Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a human homolog of rat elastase IV (HEIV) expressed in pancreas tissue. The present invention also provides for antisense molecules to the nucleotide sequences which encode HEIV, hybridization probes or oligonucleotides for the detection of HEIV-encoding nucleotide sequences, and a diagnostic test based on HEIV-encoding nucleic acid molecules. The present invention further provides for genetically engineered host cells for the expression of HEIV, biologically active HEIV, antibodies capable for binding specifically to HEIV, and treatment methods comprising administration of compounds, such antibodies or inhibitors, capable of binding HEIV to alter its activity.Type: GrantFiled: November 7, 1997Date of Patent: January 5, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott M. Braxton, Dinh Diep, Angelo M. Delegeane
-
Patent number: 5840562Abstract: The present invention provides a polynucleotide (ncp) which identifies and encodes a novel cysteine protease (NCP) expressed in cells of both the adrenal gland and human umbilical vein endothelium. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and host cells for the production of purified NCP peptide, antibodies capable of binding to NCP, inhibitors which bind to NCP and pharmaceutical compositions based on NCP specific antibodies or inhibitors. The invention specifically provides for diagnostic assays based on altered ncp expression and which allow identification of such a condition. These assays utilize probes designed from ncp encoding or controlling nucleic acid sequences or antibodies specific for the NCP.Type: GrantFiled: September 12, 1997Date of Patent: November 24, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Dinh Diep, Scott Michael Braxton, Angelo M. Delegeane
-
Patent number: 5808001Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new human interleukin-1 converting enzyme homolog (ICEY). The present invention also provides for antisense molecules to the nucleotide sequences which encode ICEY, expression vectors for the production of purified ICEY, antibodies capable of binding specifically to ICEY, hybridization probes or oligonucleotides for the detection of ICEY-encoding nucleotide sequences, genetically engineered host cells for the expression of ICEY, diagnostic tests for activation of monocyte/macrophages based on ICEY-encoding nucleic acid molecules, and use of the protein to produce antibodies capable of binding specifically to the protein and use of the protein to screen for inhibitors.Type: GrantFiled: July 25, 1997Date of Patent: September 15, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott Michael Braxton, Angelo M. Delegeane, Dinh Diep
-
Patent number: 5804376Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel pancreas-derived serpin (PDS) expressed in human pancreas. The present invention also provides for antisense molecules to the nucleotide sequences which encode PDS, expression vectors for the production of purified PDS, antibodies capable of binding specifically to PDS, hybridization probes or oligonucleotides for the detection of PDS-encoding nucleotide sequences, genetically engineered host cells for the expression of PDS, diagnostic tests based on PDS-encoding nucleic acid molecules and a pharmaceutical composition containing PDS capable of binding specifically to a serine protease.Type: GrantFiled: May 2, 1995Date of Patent: September 8, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott Michael Braxton, Craig G. Wilde, Dinh Diep
-
Patent number: 5738991Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a human homolog of rat elastase IV (HEIV) expressed in pancreas tissue. The present invention also provides for antisense molecules to the nucleotide sequences which encode HEIV, hybridization probes or oligonucleotides for the detection of HEIV-encoding nucleotide sequences, and a diagnostic test based on HEIV-encoding nucleic acid molecules. The present invention further provides for genetically engineered host cells for the expression of HEIV, biologically active HEIV, antibodies capable for binding specifically to HEIV, and treatment methods comprising administration of compounds, such antibodies or inhibitors, capable of binding HEIV to alter its activity.Type: GrantFiled: December 6, 1995Date of Patent: April 14, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott Michael Braxton, Dinh Diep, Angelo M. Delegeane
-
Patent number: 5700924Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel serpin (CAPE) expressed in human hypothalamus. The present invention also provides for antisense molecules to the nucleotide sequences which encode CAPE, expression vectors for the production of purified CAPE, antibodies capable for binding specifically to CAPE, hybridization probes or oligonucleotides for the detection of CAPE-encoding nucleotide sequences, genetically engineered host cells for the expression of Cape, a pharmaceutical composition containing biologically active CAPE, a diagnostic test based on CAPE-encoding nucleic acid molecules, and treatment methods comprising administration of biologically active CAPE.Type: GrantFiled: June 7, 1995Date of Patent: December 23, 1997Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott Michael Braxton, Dinh Diep, Susan G. Stuart
-
Patent number: 5654146Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new human interleukin-1 converting enzyme homolog (ICEY). The present invention also provides for expression vectors for the production of purified ICEY, hybridization probes for the detection of ICEY-encoding nucleotide sequences, genetically engineered host cells for the expression of ICEY, diagnostic tests for ICEY or for polynucleotides encoding ICEY, and use of the protein to produce antibodies capable of binding specifically to the protein and use of the protein to screen for inhibitors.Type: GrantFiled: May 31, 1995Date of Patent: August 5, 1997Assignee: Incyte Pharmaceuticals, Inc.Inventors: Scott Michael Braxton, Angelo M. Delegeane, Dinh Diep